References
1. Zhou J., Dudley M.E., Rosenberg S.A., Robbins P.F. Selective Growth. In vitro and in vivo, of individual T cell clones from tumor-infiltrating lymphocytes obtained from patients with melanoma. J Immunol. 2004; 173 (12): 7622–9. PMID: 15585890. DOI: http://dx.doi.org/10.4049/jimmunol.173.12.7622
2. Wang M., Shu X., Li M., Zhang Y., Yao Y., Huang X., Wei P., He Z., Lu J., Ying Y.A. Novel strategy conjugating PD-L1 polypeptide with doxorubicin alleviates chemotherapeutic resistance and enhances immune response in colon cancer. Res Sq. 2021; 1–19. DOI: http://dx.doi.org/10.21203/rs.3.rs-420385/v1
3. Ostrand-Rosenberg S., Horn L.A., Alvarez J.A. Novel strategies for inhibiting PD-1 pathway-mediated immune suppression while simultaneously delivering activating signals to tumor-reactive T cells. Cancer Immunol Immunother. 2016; 176: 139–48. PMID: 25792524. DOI: http://dx.doi.org/10.1007/s00262-015-1677-5
4. O’Day S.J., Hamid O., Urba W.J. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer. 2007; 110: 2614–27. PMID: 18000991. DOI: http://dx.doi.org/10.1002/cncr.23086
5. Mullins S.R., Vasilakos J.P., Deschler K., Grigsby I., Gillis P., John J., Elder M.J., Swales J., Timosenko E., Cooper Z., Dovedi S.J., Leishman A.J., Luheshi N., Elvecrog J., Tilahun A., Goodwin R., Herbst R., Tomai M.A., Wilkinson R.W. Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies. J Immunother Cancer. 2018; 8: 711. DOI: http://dx.doi.org/10.1158/1538-7445.am2018-711
6. Miliotou A.N., Papadopoulou L.C. CAR T-cell therapy: a new era in cancer immunotherapy. Curr Pharm Biotechnol. 2018; 19: 5–18. PMID: 29667553. DOI: http://dx.doi.org/10.2174/1389201019666180418095526
7. Gellrich F., Schmitz M., Beissert S., Meier F. Anti-PD-1 and Novel Combinations in the Treatment of Melanoma – An Update. J Clin Med. 2020; 9 (1): 223. PMID: 31947592. DOI: http://dx.doi.org/10.3390/jcm9010223
8. Bhatia S., Miller N.J., Lu H., Longino N.V., Ibrani D., Shinohara M.M., Byrd D.R., Parvathaneni U., Kulikauskas R., Ter Meulen J., Hsu F.J., Koelle D.M., Nghiem P. Intratumoral G100, a TLR4 agonist, induces antitumor immune responses and tumor regression in patients with merkel cell carcinoma. Clin Cancer Res. 2020; 25 (4): 1185–95. DOI: http://dx.doi.org/10.1158/1078-0432.CCR-18-0469.Intratumoral
9. Wei R., Liu S., Zhang S., Min L., Zhu S. Cellular and extracellular components in tumor microenvironment and their application in early diagnosis of cancers. Anal Cell Pathol. 2020; 2020: 6283796. DOI: http://dx.doi.org/]10.1155/2020/6283796
10. Kaufman H.L., Wolchok J.D. General Principles of Tumor Immunotherapy. Basic and Clinical Applications of Tumor Immunology. Springer Netherlands. 2008, 503 p. ISBN 978-1-4020-6086-1. DOI: http://dx.doi.org/10.1007/978-1-4020-6087-8
11. Ataullakhanov R.I., Pichugin A.V., Mel’nikova T.M., Khaitov R.M. A method of producing a substance with immunostimulating, antiviral and, antimicrobial activity, a substance produced by this method and its pharmaceutical compositions. Russian Patent Application RU 2195308, priority date: November 11, 2001. (in Russian)
12. Ghochikyan A., Pichugin A., Bagaev A., Davtyan A., Hovakimyan A., Tukhvatulin A., Davtyan H., Shcheblyakov D., Logunov D., Chulkina M., Savilova A., Trofimov D., Nelson E.L., Agadjanyan M.G., Ataullakhanov R.I. Targeting TLR-4 with a novel pharmaceutical grade plant derived agonist, Immunomax, as a therapeutic strategy for metastatic breast cancer. J Translational Medicine. 2014; 12 (1): 322. PMID: 25432242. DOI: http://dx.doi.org/10.1186/s12967-014-0322-y
13. Ataullakhanov R.I., Pichugin A.V., Shishkova N.M., Masternak T.B., Malkina E.Yu., Ulyanova L.I., Stetsenko O.N. Cellular mechanisms of immunomodulating action of «Immunomax». Immunologiya. 2005; 2: 111–20. (in Russian)
14. Bagaev A., Pichugin A., Nelson E.L., Agadjanyan M.G., Ghochikyan A., Ataullakhanov R.I. Anti-cancer mechanisms in two murine bone marrow-derived DC subsets activated with Toll-like receptor 4 agonists. J Immunol. 2019; 200 (8): 2656–69. PMID: 29500244. DOI: http://dx.doi.org/10.4049/jimmunol.1701126.Anti-cancer
15. Lebedeva E.S., Bagaev A.V., Garaeva A.Y., Chulkina M.M., Pichugin A.V., Ataullakhanov R.I. The cooperative interaction of TLR4-, TLR9- and NOD2-signaling pathways in mouse macrophages. Immunologiya. 2018; 39 (1): 4–11. DOI: http://dx.doi.org/10.18821/0206-4952-2018-39-1-4-11 (in Russian)
16. Lebedeva E., Bagaev A., Pichugin A., Chulkina M., Lysenko A., Tutykhina I., Shmarov M., Logunov D., Naroditsky B., Ataullakhanov R. The differences in immunoadjuvant mechanisms of TLR3 and TLR4 agonists on the level of antigen-presenting cells during immunization with recombinant adenovirus vector. BMC immunology. 2018; 19 (1): 26. PMID: 30055563. DOI: http://dx.doi.org/10.1186/s12865-018-0264-x
17. Nikonova A., Pichugin A., Chulkina M., Lebedeva E., Gaisina A., Shilovskiy I., Ataullakhanov R., Khaitov M., Khaitov R. The TLR4 Agonist Immunomax Affects the Phenotype of Mouse Lung Macrophages during Respiratory Syncytial Virus Infection. Acta Naturae. 2018; 10 (4): 95–9. PMID: 30713767. (in Russian)
18. Lebedeva E.S., Bagaev A.V., Chulkina M.M., Pichugin A.V., Ataullakhanov R.I. Synergistic activation of gene transcription encoding type I interferons and cytokines in macrophages and dendritic cells by the combinations of two PRR-agonists. Immunologiya. 2017; 38 (1): 64–71. DOI: http://dx.doi.org/10.18821/0206-4952-2017-38-1-64-71 (in Russian)
19. Pichugin A.V., Bagaev A.V., Lebedeva E.S., Chulkina M.M., Ataullakhanov R.I. Synergistic cytokine production by murine dendritic cells in response to their simultaneous activation with pairs of agonists of different innate immune receptors. Immunologiya. 2017; 38 (1): 118–23. DOI: http://dx.doi.org/10.18821/0206-4952-2017-38-2-118-123 (in Russian)
20. Lebedeva E.S., Bagaev A.V., Chulkina M.M., Pichugin A.V., Ataullakhanov R.I. NF-kB-, but not MAPK-signaling pathway determines synergistic response of macrophages to the simultaneous activation of two types receptors TLR4 + NOD2 or TLR9 + NOD2. Immunologiya. 2017; 38 (2): 76–82. DOI: http://dx.doi.org/10.18821/0206-4952-2017-38-2-76-82 (in Russian)
21. Lebedeva E.S., Bagaev A.V., Chulkina M.M., Pichugin A.V., Lysenko A.A., Shmarov M.M., Logunov D.Yu., Naroditsky B.S., Ataullakhanov R.I. Mechanisms of TLR4 agonists enhance the expression of target protein in the composition of the adenoviral vector into antigen presenting cells. Immunologiya. 2017; 38 (6): 295–306. DOI: http://dx.doi.org/10.18821/0206-4952-2017-38-6-295-306 (in Russian)
22. Bagaev A.V., Pichugin A.V., Lebedeva E.S., Lysenko A.A., Shmarov M.M., Logunov D.Yu., Naroditsky B.S., Ataullakhanov R.I., Khaitov R.M., Gintsburg A.L. Influence of TLR-agonists on expression by antigen-presenting cells of the target protein antigen encoded in adenoviral vector. Immunologiya. 2015; 36 (4): 188–95. (in Russian)
23. Demicheli R., Abbattista A., Miceli R., Valagussa P., Bonadonna G. Time distribution of the recurrence risk for breast cancer patients undergoing mastectomy: Further support about the concept of tumor dormancy. Breast Cancer Res Treat. 1996; 41 (2): 177–85. PMID: 8944336. DOI: http://dx.doi.org/10.1007/BF01807163
24. Saphner T., Tormey D.C., Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol. 1996; 14 (10): 2738–46. PMID: 8874335. DOI: http://dx.doi.org/10.1200/JCO.1996.14.10.2738
25. Karrison T.G., Ferguson D.J., Meier P. Dormancy of mammary carcinoma after mastectomy. J Natl Cancer Inst. 1999; 91 (1): 80–5. PMID: 9890174. DOI: http://dx.doi.org/10.1093/jnci/91.1.80
26. Pichugin A.V., Bagaev A.V., Chulkina M.M., Berzhitskaya D.A., Shishkova N.M., Ataullakhanov R.I. Immunomodulator «Immunomax» activates dendritic cells. Immunologiya. 2015; 36 (4): 200–5. (in Russian)